Cargando…

Author Correction: Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Detalles Bibliográficos
Autores principales:	Wang, Xuan, Xiong, Zhiyong, Liu, Zhen, Huang, Xing, Jiang, Xiaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414596/ https://www.ncbi.nlm.nih.gov/pubmed/30862806 http://dx.doi.org/10.1038/s41598-019-40291-5

Ejemplares similares

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma
por: Wang, Xuan, et al.
Publicado: (2018)

Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model
por: Wang, Xuan, et al.
Publicado: (2014)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

Construction and Periplasmic Expression of the Anti-EGFRvIII ScFv Antibody Gene in Escherichia coli
por: Dewi, Kartika Sari, et al.
Publicado: (2016)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM)
por: di Polidoro, Angela Costagliola, et al.
Publicado: (2022)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Homogeneous antibody–angiopep 2 conjugates for effective brain targeting
por: Anami, Yasuaki, et al.
Publicado: (2022)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Engineering hematopoietic stem cells to create melanoma specific CTL
por: Vatakis, Dimitrios
Publicado: (2012)

A new dynamic model of three cell interactions for CTL responses
por: Ahmed, Khawaja Ashfaque, et al.
Publicado: (2012)

Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model
por: Choi, Jin Myung, et al.
Publicado: (2022)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

Influence of the Drug Position on Bioactivity in Angiopep-2—Daunomycin Conjugates
por: Pethő, Lilla, et al.
Publicado: (2023)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy
por: Xiang, Jing, et al.
Publicado: (2023)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Author Correction: Selective, high-contrast detection of syngeneic glioblastoma in vivo
por: Banati, Richard B., et al.
Publicado: (2020)

Author Correction: The white matter is a pro-differentiative niche for glioblastoma
por: Brooks, Lucy J., et al.
Publicado: (2022)

Author Correction: Reconstructing the maize leaf regulatory network using ChIP-seq data of 104 transcription factors
por: Tu, Xiaoyu, et al.
Publicado: (2023)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

Poly(p-phenylenevinylene) nanoparticles modified with antiEGFRvIII for specific glioblastoma therapy
por: Liang, Yuchao, et al.
Publicado: (2021)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Author Correction: Multivariate information theory uncovers synergistic subsystems of the human cerebral cortex
por: Varley, Thomas F., et al.
Publicado: (2023)

Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma
por: Xie, Ruoxi, et al.
Publicado: (2021)

Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
por: Krishna Moorthy, Nivetha, et al.
Publicado: (2021)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
por: Zong, Zhenkun, et al.
Publicado: (2019)

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review
por: Habib, Saffiya, et al.
Publicado: (2022)

Author Correction: Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia
por: Huang, Zhu, et al.
Publicado: (2023)

Author Correction: Identification of novel dysregulated key genes in Breast cancer through high throughput ChIP-Seq data analysis
por: Raj, Utkarsh, et al.
Publicado: (2020)

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
por: Babu, Ranjith, et al.
Publicado: (2012)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i6pa8kamt35bq13otqmv1ho7nq